Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May 10;34(10):1747-60.
doi: 10.1002/sim.6436. Epub 2015 Jan 28.

Surrogates of protection in repeated low-dose challenge experiments

Affiliations

Surrogates of protection in repeated low-dose challenge experiments

Dustin M Long et al. Stat Med. .

Abstract

A critical step toward developing a successful vaccine to control the human immunodeficiency virus pandemic entails evaluation of vaccine candidates in non-human primates (NHPs). Historically, these studies have usually entailed challenges (i.e., exposures) with very high doses of a simian version of human immunodeficiency virus, resulting in infection of all NHPs in the experiment after a single challenge. More recently, researchers have begun to conduct repeated low-dose challenge (RLC) studies in NHPs that are believed to more closely mimic typical exposure in natural human transmission settings. One objective of RLC studies is to assess whether measured immune responses to vaccination can serve as surrogate endpoints for the primary endpoint of interest, namely infection. In this paper, different designs of RLC studies for assessing a binary surrogate of protection are considered.

Keywords: HIV; causal inference; immunogenicity; infectious diseases; transmission probability; vaccine.

PubMed Disclaimer

References

    1. Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu S, Johnson R, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Medicine. 2008;5(8):e173. - PMC - PubMed
    1. Fauci A, Johnston M, Dieffenbach C, Burton D, Hammer S, Hoxie J, Martin M, Overbaugh J, Watkins D, Mahmoud A, Greene W. HIV vaccine research: the way forward. Science. 2008;321:530–532. - PubMed
    1. Feinberg MB, Moore JP. AIDS vaccine models: challenging challenge viruses. Nature Medicine. 2002;8:207–210. - PubMed
    1. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2013;505:502–508. - PMC - PubMed
    1. García-Lerma J, Otten R, Qari S, Jackson E, Cong M, Masciotra S, Luo W, Kim C, Adams D, Monsour M, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5:e28. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources